The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results

JACC Podcast

In this episode, Dr. Valentin Fuster explores findings from the Phase 2 OCEAN-LDO trial assessing the off-treatment effects of the RNA-based drug alpcisiran on lipoprotein(a) [Lp(a)] levels. The study found that high doses of alpcisiran reduced Lp(a) levels by up to 95% during treatment, with a sustained reduction of 27-76% persisting up to 96 weeks after discontinuation, and no new safety concerns emerged.